Spero Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 46
- Market Cap
- $74.5M
- Introduction
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. M...
Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT03376529
- Locations
- 🇬🇧
Simbec Research, Ltd., Merthyr Tydfil,, Mid Glamorgan, United Kingdom
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2017-10-05
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT03022175
- Locations
- 🇦🇺
CMAX - A division of IDT Australia, Limited, Adelaide, South Australia, Australia
© Copyright 2024. All Rights Reserved by MedPath